Three States Challenge Cannabis Rescheduling in Federal Court Appeal

Three conservative states have escalated their opposition to federal cannabis rescheduling by filing a formal challenge in the U.S. Court of Appeals for the D.C. Circuit. Nebraska, Indiana, and Louisiana submitted their petition on May 22, directly contesting the Acting Attorney General's decision to reclassify FDA-approved and state-licensed cannabis from Schedule I to Schedule III under the Controlled Substances Act.

The legal challenge introduces fresh uncertainty into what many industry observers considered a settled regulatory shift. The rescheduling process, which began with the Biden administration's directive to review cannabis classification, had progressed through DEA consideration and public comment periods. This multi-state opposition represents the first coordinated legal effort to block the federal policy change that would reduce cannabis penalties and enable standard business tax deductions for licensed operators.

The timing of this challenge creates immediate complications for cannabis companies planning around Schedule III benefits. Operators currently face Section 280E tax restrictions that prevent deducting ordinary business expenses, effectively creating tax rates exceeding 70% in some cases. The potential reversal or delay of rescheduling would force companies to maintain current financial planning assumptions while legal proceedings unfold, likely extending the timeline for meaningful federal reform.

The three plaintiff states represent jurisdictions with restrictive cannabis policies, suggesting their challenge stems from concerns about federal rescheduling undermining state-level prohibition efforts. Their legal standing will depend on demonstrating concrete harm from the rescheduling decision, which could prove difficult given that Schedule III classification maintains federal prohibition while reducing criminal penalties. The D.C. Circuit's handling of this case will establish important precedent for state authority to challenge federal drug scheduling decisions.

This legal development adds another layer of complexity to an already uncertain federal landscape. While rescheduling appeared to be advancing through administrative channels, the court challenge could delay implementation indefinitely. Cannabis operators must now factor potential legal setbacks into their strategic planning, particularly regarding expansion decisions and capital allocation that depend on improved federal tax treatment.